With just 2 doses in 1 month1
Help provide Higher rates of protection for patients aged 40-70 years

HEPLISAV-B provided statistically significantly higher rates of protective immunity in patients aged 40-70 years1,16

IN TRIAL 2: Statistically significantly higher rates of protection vs Engerix-B® at every timepoint

Ages 40-70 immunity rates in trial 2 Ages 40-70 immunity rates in trial 2

*Protective immunity defined as antibody concentration ≥10 mIU/mL.

Engerix-B is a registered trademark of the GSK group of companies.



Study Results — Ages 40-70 (Trial 2)
HEPLISAV-B Hepatitis B Vaccine (Recombinant), Adjuvantedâ„¢ HEPLISAV-B Hepatitis B Vaccine (Recombinant), Adjuvantedâ„¢

Call 1-84-HEPLISAV (1-844-375-4728)
8 AM to 8 PM, ET, Monday through Friday